Isatuximab

Drug Profile

Isatuximab

Alternative Names: Anti-CD38 monoclonal antibody - Sanofi; hu38SB19; SAR-650984

Latest Information Update: 01 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ImmunoGen
  • Developer Sanofi
  • Class Antibodies; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; CD38 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Multiple myeloma
  • Phase II Acute lymphoblastic leukaemia; T cell lymphoma

Most Recent Events

  • 23 Jun 2017 Sanofi plans the phase I/II trial for Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA (NCT03194867)
  • 02 Jun 2017 Efficacy and adverse events data from a phase Ib trial in multiple myeloma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 30 May 2017 ImmunoGen and Sanofi amends a licensing agreement granting exclusive, fully-paid license of isatuximab to Sanofi
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top